Comparative Antibiofilm Efficacy of Meropenem Alone and in Combination with Colistin in an In Vitro Pharmacodynamic Model by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae

We compared the efficacies of meropenem alone and in combination with colistin against two strains of extended-spectrum-β-lactamase-producing Klebsiella pneumoniae, using an in vitro pharmacodynamic model that mimicked two different biofilm conditions. Meropenem monotherapy achieved remarkable efficacy (even a bactericidal effect) under all conditions, whereas colistin was almost inactive and resistance emerged. ABSTRACT We compared the efficacies of meropenem alone and in combination with colistin against two strains of extended-spectrum-β-lactamase-producing Klebsiella pneumoniae, using an in vitro pharmacodynamic model that mimicked two different biofilm conditions. Meropenem monotherapy achieved remarkable efficacy (even a bactericidal effect) under all conditions, whereas colistin was almost inactive and resistance emerged. The addition of colistin to meropenem produced no relevant benefits, in contrast to experiences with other microorganisms.

[1]  J. Ariza,et al.  Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model. , 2019, International journal of antimicrobial agents.

[2]  E. Roilides,et al.  Dose-Dependent Synergistic Interactions of Colistin with Rifampin, Meropenem, and Tigecycline against Carbapenem-Resistant Klebsiella pneumoniae Biofilms , 2019, Antimicrobial Agents and Chemotherapy.

[3]  C. Clancy,et al.  Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae In Vitro or Suppress Emergence of Ceftazidime-Avibactam Resistance , 2018, Antimicrobial Agents and Chemotherapy.

[4]  N. Lloberas,et al.  Evaluation of linezolid or trimethoprim/sulfamethoxazole in combination with rifampicin as alternative oral treatments based on an in vitro pharmacodynamic model of staphylococcal biofilm. , 2018, International journal of antimicrobial agents.

[5]  L. Leibovici,et al.  Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. , 2018, The Lancet. Infectious diseases.

[6]  A. Spormann,et al.  Spatiotemporal pharmacodynamics of meropenem- and tobramycin-treated Pseudomonas aeruginosa biofilms , 2017, The Journal of antimicrobial chemotherapy.

[7]  E. Kara,et al.  Investigation of the effects of various antibiotics against Klebsiella pneumoniae biofilms on in vitro catheter model , 2017 .

[8]  C. Giske,et al.  Evaluation of antibacterial activities of colistin, rifampicin and meropenem combinations against NDM-1-producing Klebsiella pneumoniae in 24 h in vitro time-kill experiments. , 2016, The Journal of antimicrobial chemotherapy.

[9]  R. Hancock,et al.  Antibiofilm Peptides: Potential as Broad-Spectrum Agents , 2016, Journal of bacteriology.

[10]  N. Høiby,et al.  Increased bactericidal activity of colistin on Pseudomonas aeruginosa biofilms in anaerobic conditions , 2015, Pathogens and disease.

[11]  Brian T. Tsuji,et al.  Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria , 2015, Infectious Diseases and Therapy.

[12]  Suzana M. Ribeiro,et al.  Antibiofilm Peptides Increase the Susceptibility of Carbapenemase-Producing Klebsiella pneumoniae Clinical Isolates to β-Lactam Antibiotics , 2015, Antimicrobial Agents and Chemotherapy.

[13]  Á. Soriano,et al.  Gram-negative prosthetic joint infection: outcome of a debridement, antibiotics and implant retention approach. A large multicentre study. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[14]  J. Li,et al.  Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model. , 2014, The Journal of antimicrobial chemotherapy.

[15]  Grace C. Lee,et al.  Polymyxins and Doripenem Combination Against KPC-Producing Klebsiella pneumoniae , 2013, Journal of clinical medicine research.

[16]  A. Oliver,et al.  High β-Lactamase Levels Change the Pharmacodynamics of β-Lactam Antibiotics in Pseudomonas aeruginosa Biofilms , 2012, Antimicrobial Agents and Chemotherapy.

[17]  D. Paterson,et al.  The Combination of Colistin and Doripenem Is Synergistic against Klebsiella pneumoniae at Multiple Inocula and Suppresses Colistin Resistance in an In Vitro Pharmacokinetic/Pharmacodynamic Model , 2012, Antimicrobial Agents and Chemotherapy.

[18]  N. Høiby,et al.  In Vivo Pharmacokinetics/Pharmacodynamics of Colistin and Imipenem in Pseudomonas aeruginosa Biofilm Infection , 2012, Antimicrobial Agents and Chemotherapy.

[19]  Brian T. Tsuji,et al.  Synergistic Killing of Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula by Colistin Combined with Doripenem in an In Vitro Pharmacokinetic/Pharmacodynamic Model , 2011, Antimicrobial Agents and Chemotherapy.

[20]  A Forrest,et al.  Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients , 2011, Antimicrobial Agents and Chemotherapy.

[21]  Á. Soriano,et al.  Outcome of Acute Prosthetic Joint Infections Due to Gram-Negative Bacilli Treated with Open Debridement and Retention of the Prosthesis , 2009, Antimicrobial Agents and Chemotherapy.

[22]  J. Turnidge,et al.  In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. , 2008, The Journal of antimicrobial chemotherapy.

[23]  T. Tolker-Nielsen,et al.  Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB‐oprM genes , 2008, Molecular microbiology.

[24]  M. Hamilton,et al.  Statistical assessment of a laboratory method for growing biofilms. , 2005, Microbiology.

[25]  Paul Stoodley,et al.  Bacterial biofilms: from the Natural environment to infectious diseases , 2004, Nature Reviews Microbiology.

[26]  D. Nicolau,et al.  Pharmacokinetics of High-Dose Meropenem in Adult Cystic Fibrosis Patients , 2001, Chemotherapy.

[27]  M. R. Brown,et al.  Biofilms and beta-lactam activity. , 1998, The Journal of antimicrobial chemotherapy.

[28]  R. Eng,et al.  Bactericidal effects of antibiotics on slowly growing and nongrowing bacteria , 1991, Antimicrobial Agents and Chemotherapy.